VirTra Shines with Record-Breaking Revenue, Beam Global Beats Expectations, Eloxx Pharmaceuticals Misses Estimates, Ducommun Launches Public Offering
- May 15th, 2023
- 637 views
VirTra, Inc. (Nasdaq: VTSI) achieved remarkable double-digit millions in quarterly revenue for the first time, surpassing expectations with Q1 2023 earnings per share (EPS) of $0.27 compared to the consensus estimate of $0.04.
In after-hours trading, $VTSI is currently valued at $6.99, experiencing a notable increase of $1.07 (+18.07%).
Beam Global (Nasdaq: BEEM) reported a loss of $0.38 per share for the first quarter 2023, performing better than the consensus estimate of a loss of $0.42 per share.
$BEEM is trading at $11.69 in after-hours, reflecting a significant gain of $1.66 (+16.55%).
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) reported a loss of $2.88 per share for Q1 2023, worse than the consensus estimate of a loss of $2.55 per share.
In after-hours trading, $ELOX is currently valued at $8.23, experiencing a decline of $2.67 (-24.50%).
Ducommun Incorporated (NYSE: DCO) announced the launch of an underwritten public offering of 2,000,000 shares of its common stock.
Following this announcement, $DCO is trading at $43.75 in after-hours, indicating a decrease of $4.67 (-9.64%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Countdown to Earnings: Nutanix, CrowdStrike, and Synopsys on Deck
August 23rd, 2026Investors Eye Semtech, Intuit, and nCino as Earnings Loom
August 22nd, 2026FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
August 21st, 2026




Member Login